

Putting NICE guidance into practice

Costing statement: Renal cell carcinoma – axitinib

Implementing the NICE guidance on Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

Published: February 2015

NHS England commissions this technology as part of specialised cancer services.

There are currently no second-line drugs approved by NICE for treating advanced renal cell carcinoma after failure of first-line treatments. The estimated cost of implementing the guidance is £14 million (including VAT) for the population of England. This cost is before taking into account the discount available in the patient access scheme. The population eligible for treatment is approximately 1,500 people per year in England.

The Department of Health and the company have agreed that axitinib will be available to the NHS with a patient access scheme which makes axitinib available with a discount. The size of the discount is commercial in confidence. It is the responsibility of the company to communicate the details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to Stephen.skyrme@pfizer.com.

